THIOPURINE METHYLTRANSFERASE GENOTYPE PREDICTS THERAPY-LIMITING SEVERE TOXICITY FROM AZATHIOPRINE

Background: Substantial hematologic toxicity limits the use of azathio prine. Objective: To evaluate 1) polymorphic inactivation of azathiopr ine by thiopurine methyltransferase and 2) clinical toxicity. Design: Prospective cohort study. Setting: Two rheumatology units. Patients: 6 7 patients for whom azathioprine was prescribed as second-line therapy for rheumatic disease. Measurements: Polymerase chain reaction-based assays were used to detect mutations in thiopurine methyltransferase. The primary end point was discontinuation of azathioprine therapy beca use of toxicity. Results: Six of 67 patients (9%) were heterozygous fo r mutant thiopurine methyltransferase alleles. Five of the 6 patients discontinued therapy within 1 month of starting treatment because of l ow leukocyte counts. The sixth patient did not adhere to treatment. Pa tients with wild-type thiopurine methyltransferase alleles received th erapy longer than did patients with mutant alleles (median duration of therapy, 39 weeks [range, 6 to 180 weeks] and 2 weeks [range, 2 to 4 weeks], respectively; P = 0.018). Conclusion: Analysis of thiopurine m ethyltransferase genotype is a quick way to identify patients at risk for acute toxicity from azathioprine.